Prostate Cancer: Our Clinical Trials

In addition to providing excellent care, Memorial Sloan Kettering is constantly working to improve treatment for prostate cancer. Our clinical trials enable us to deliver state-of-the-art care, and our physicians lead a large number of trials of innovative approaches to treatment for men at all clinical states of prostate cancer. These trials test new drugs and drug combinations, surgical and radiation therapy techniques, innovative diagnostic technologies, and strategies for preserving quality of life for men undergoing treatment.

Choosing Memorial Sloan Kettering for your care may give you access to new treatment options before they are widely available elsewhere. Our experts can help to determine which clinical trials are right for you. For more information about our clinical trials, call our Physician Referral Service at 800-525-2225, or talk with your doctor.

Memorial Sloan Kettering is the coordinating center for the Prostate Cancer Clinical Trials Consortium (PCCTC), a national organization that includes 13 leading academic centers. The PCCTC is engaged in the development of new medications and new combined-modality approaches against aggressive disease that will affect lifespan or quality of life. We have long been at the forefront of bringing needed new drugs to patients quickly. Our medical oncologists have leadership positions within the consortium and other national clinical trial groups focusing on prostate cancer, and created the infrastructure for the development and evaluation of new prostate cancer drugs.

The following prostate cancer clinical trials at Memorial Sloan Kettering are currently enrolling new patients. To learn more about a study, choose from the list below.

Showing 41 trials
Title Investigatorsort icon
A Phase II Study Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Low-Risk Prostate Cancer
[Protocol 11-056]
Zelefsky, Michael, MD
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
[Protocol 11-112]
Zaider, Talia, PhD
The Prevention of Delirium and Complications Associated with Surgical Treatments (PODCAST) Clinical Trial
Newly Diagnosed & Relapsed/Refractory
[Protocol 13-240]
Veselis, Robert, MD
A Phase IV Study of Enzalutamide in Men with Metastatic Prostate Cancer Who Are at Risk for Seizures
[Protocol 13-231]
Slovin, Susan, MD, PhD
Adoptive Transfer of Autologous T Cells Targeted to Prostate-Specific Membrane Antigen for the Treatment of Metastatic Castration-Resistant Prostate Cancer
[Protocol 09-036]
Slovin, Susan, MD, PhD
A Phase II Study of Abiraterone with or without Cabazitaxel in Patients with Metastatic Castration-Resistance Prostate Cancer
[Protocol 14-046]
Slovin, Susan, MD, PhD
A Phase II Study of Abiraterone, Prednisone, and Degarelix in Men with Recurrent Prostate Cancer and a Rising PSA
[Protocol 12-187]
Scher, Howard, MD
A Pilot Study of a Geriatric-Specific Psychoeducational Intervention for Elderly Cancer Patients
[Protocol 09-116]
Roth, Andrew, MD
A Phase I Study of BMS-986015 with Ipilimumab in Patients with Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Melanoma
[Protocol 12-283]
Rizvi, Naiyer, MD
A Study of Degarelix Before Prostatectomy in Patients with Intermediate- to High-Risk Prostate Cancer
[Protocol 11-182]
Rathkopf, Dana, MD
A Phase IA/B Study of CC-115 in Castration-Resistant Prostate Cancer
[Protocol 12-080]
Rathkopf, Dana, MD
A Phase III Study of ARN-509 versus Placebo in Men with Non-Metastatic Castration-Resistant Prostate Cancer
[Protocol 13-243]
Rathkopf, Dana, MD
A Phase II Study of MLN0128 in Men with Castration-Resistant Prostate Cancer
[Protocol 13-143]
Rathkopf, Dana, MD
A Phase Ib Study of ARN-509 plus Everolimus in Men with Progressive Metastatic Castration-Resistant Prostate Cancer After Abiraterone Therapy
[Protocol 13-025]
Rathkopf, Dana, MD
Microvascular Reconstruction for Advanced-Stage Head and Neck Cancer Patients: A Prospective Analysis of Quality of Life and Symptom Relief
[Protocol 07-150]
Pusic, Andrea, MD, MHS
Clinical Significance of Germline BRCA Mutations
[Protocol 96-051]
Offit, Kenneth, MD
Decision-Making about Active Surveillance among Prostate Cancer Patients and Their Partners/Allies
[Protocol 13-076]
Nelson, Christian, PhD
The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men with Prostate Cancer Age 65 and Older
[Protocol 06-084]
Nelson, Christian, PhD
Identifying and Measuring Depression in Older People with Cancer
[Protocol 14-101]
Nelson, Christian, PhD
A Phase III Study of Enzalutamide Alone or with Abiraterone and Prednisone for Metastatic Castration-Resistant Prostate Cancer
[Protocol 13-247]
Morris, Michael, MD
[18F]-Deoxy-D-Glucose (FDG) and [18F] Dihydro-Testosterone PET Imaging in Patients with Progressive Prostate Cancer
[Protocol 00-095]
Morris, Michael, MD
Development of Psychotherapeutic Interventions for Parents Who Lost a Child to Cancer
[Protocol 14-102]
Lichtenthal, Wendy, PhD
The Lymphedema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors, and Impact in Newly Diagnosed Patients
[Protocol 12-190]
Leitao, Mario, MD
Evaluation of Physical Function and Quality of Life Before and After Non-Radical Surgery for Stage I Cervical Cancer
Newly Diagnosed
[Protocol 13-210]
Leitao, Mario, MD
Quality of Life Assessment in Breast Cancer Patients with Radiation-Induced Telangiectasias Treated with Pulsed Dye Laser
[Protocol 13-013]
Lee, Erica, MD
A Study Assessing the Use of Dual Handset Phones to Improve Communication with Inpatients Who Have Limited English Proficiency
[Protocol 14-042]
Kumar, Chhavi, MD
A Study Assessing the Safety and Tolerability of Supervised Aerobic Exercise Training in Women with Metastatic Breast Cancer
[Protocol 14-170]
Jones, Lee, PhD
A Study of Physician Communication Skills to Promote Patients' Transition to Survivorship
[Protocol 11-180]
Horwitz, Steven, MD
A Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
[Protocol 07-041]
Eastham, James, MD
Prognostic Awareness and Patient-Physician Communication in Malignant Glioma
[Protocol 13-253]
Diamond, Eli, MD
A Phase III Study of Armodafinil versus Placebo to Reduce Cancer-Related Fatigue in Patients with High-Grade Glioma
Newly Diagnosed & Relapsed/Refractory
[Protocol 14-040]
Diamond, Eli, MD
A Phase I/II Study of Ipilimumab Given with Abiraterone and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer
[Protocol 12-120]
Danila, Daniel, MD
A Phase II Study of MLN8237 in Patients with Advanced Prostate Cancer
[Protocol 13-042]
Danila, Daniel, MD
A Phase I Study of DSTP3086S in Patients with Metastatic Castration-Resistant Prostate Cancer
[Protocol 11-016]
Danila, Daniel, MD
Electronic Patient-Reported Outcomes from Home in Patients Recovering from Major Gynecologic Cancer Surgery: Measuring Symptoms and Quality of Life
[Protocol 08-155]
Chi, Dennis, MD
Acupuncture for Chronic Lymphedema After Breast Cancer Treatment
[Protocol 12-210]
Cassileth, Barrie, PhD
Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life
[Protocol 10-071]
Blinder, Victoria, MD
Surviving Oropharynx Cancer: Long-Term Impact of Human Papillomavirus on Quality of Life
[Protocol 10-111]
Baxi, Shrujal, MD
A Phase I Study of AM0010 in Patients with Advanced Solid Tumors
[Protocol 13-224]
Autio, Karen, MD
A Phase II Study of Degarelix plus Ipilimumab with Radical Prostatectomy in Men Newly Diagnosed with Metastatic Prostate Cancer
[Protocol 13-134]
Autio, Karen, MD
Care for the Cancer Caregiver: A Meaning-Based Workshop to Help Manage Caregiver Burden
Newly Diagnosed & Relapsed/Refractory
[Protocol 14-208]
Applebaum, Allison, PhD